SciSparc (SPRC) Competitors $0.32 0.00 (-1.05%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$0.32 0.00 (-0.93%) As of 06/13/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. CTXR, PHIO, ME, AYTU, LIPO, ATHA, NEUP, NERV, AIMD, and BCTXShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Citius Pharmaceuticals (CTXR), Phio Pharmaceuticals (PHIO), 23andMe (ME), Aytu BioPharma (AYTU), Lipella Pharmaceuticals (LIPO), Athira Pharma (ATHA), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Minerva Neurosciences (NERV), Ainos (AIMD), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Its Competitors Citius Pharmaceuticals Phio Pharmaceuticals 23andMe Aytu BioPharma Lipella Pharmaceuticals Athira Pharma Neuphoria Therapeutics Inc. - Common Stock Minerva Neurosciences Ainos BriaCell Therapeutics Citius Pharmaceuticals (NASDAQ:CTXR) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership. Does the MarketBeat Community prefer CTXR or SPRC? Citius Pharmaceuticals received 212 more outperform votes than SciSparc when rated by MarketBeat users. However, 66.67% of users gave SciSparc an outperform vote while only 62.21% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCitius PharmaceuticalsOutperform Votes21462.21% Underperform Votes13037.79% SciSparcOutperform Votes266.67% Underperform Votes133.33% Is CTXR or SPRC more profitable? SciSparc's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -51.69% -37.60% SciSparc N/A N/A N/A Which has more risk and volatility, CTXR or SPRC? Citius Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Which has stronger valuation & earnings, CTXR or SPRC? SciSparc has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/ASciSparc$1.31M2.76-$5.12MN/AN/A Do insiders & institutionals have more ownership in CTXR or SPRC? 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of SciSparc shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate CTXR or SPRC? Citius Pharmaceuticals currently has a consensus price target of $54.50, indicating a potential upside of 6,131.42%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Citius Pharmaceuticals is more favorable than SciSparc.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80SciSparc 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor CTXR or SPRC? In the previous week, Citius Pharmaceuticals had 6 more articles in the media than SciSparc. MarketBeat recorded 8 mentions for Citius Pharmaceuticals and 2 mentions for SciSparc. SciSparc's average media sentiment score of 1.43 beat Citius Pharmaceuticals' score of 0.43 indicating that SciSparc is being referred to more favorably in the news media. Company Overall Sentiment Citius Pharmaceuticals Neutral SciSparc Positive SummaryCitius Pharmaceuticals beats SciSparc on 8 of the 15 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.60M$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E RatioN/A8.4626.7519.66Price / Sales2.76261.91403.98152.07Price / CashN/A65.8538.2534.64Price / Book0.026.526.964.59Net Income-$5.12M$143.26M$3.23B$248.23M7 Day Performance1.58%-0.21%-1.22%-1.07%1 Month Performance4.94%10.62%6.34%2.59%1 Year Performance-65.48%3.63%33.05%13.50% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.9843 of 5 stars$0.32-1.0%N/A-65.5%$3.60M$1.31M0.004Short Interest ↓Gap DownCTXRCitius Pharmaceuticals2.3665 of 5 stars$1.37+61.0%$54.50+3,878.1%-94.4%$13.46MN/A0.0020Gap UpHigh Trading VolumePHIOPhio Pharmaceuticals3.9568 of 5 stars$2.79-5.7%$14.00+401.8%-64.1%$13.39MN/A-0.2610Positive NewsShort Interest ↓Gap DownME23andMeN/A$0.50-35.3%N/A-93.7%$13.36M$208.78M-0.03770News CoverageGap DownHigh Trading VolumeAYTUAytu BioPharma1.4666 of 5 stars$2.11+5.5%N/A-31.8%$13.02M$81.66M-1.46160Short Interest ↓High Trading VolumeLIPOLipella Pharmaceuticals2.2377 of 5 stars$2.91-2.7%N/A-53.0%$13M$536.36K-0.684Positive NewsATHAAthira Pharma3.0297 of 5 stars$0.33-8.1%$13.83+4,079.3%-88.0%$12.92MN/A-0.1240Positive NewsGap DownNEUPNeuphoria Therapeutics Inc. - Common Stock1.9948 of 5 stars$6.82-0.7%$21.00+207.9%N/A$12.92M$15.66M0.00N/AGap UpNERVMinerva Neurosciences3.3882 of 5 stars$1.84flat$5.00+171.7%-45.5%$12.87MN/A-4.189AIMDAinos1.1845 of 5 stars$0.62-6.2%N/A-42.7%$12.84M$106.21K-0.4840Positive NewsGap DownBCTXBriaCell Therapeutics1.8343 of 5 stars$3.48+1.2%$32.00+819.5%-85.2%$12.76MN/A-0.268Short Interest ↑ Related Companies and Tools Related Companies CTXR Alternatives PHIO Alternatives ME Alternatives AYTU Alternatives LIPO Alternatives ATHA Alternatives NEUP Alternatives NERV Alternatives AIMD Alternatives BCTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
